Published in Am J Med on July 01, 1975
Pericardial heart disease: its morphologic features and its causes. Proc (Bayl Univ Med Cent) (2005) 1.39
Clinical review: intrapericardial fibrinolysis in management of purulent pericarditis. Crit Care (2011) 1.12
Bilateral empyema and purulent pericarditis due to Haemophilus influenzae capsular type b. Thorax (1988) 1.10
Purulent pericarditis in children: an analysis of 28 cases. Thorax (1977) 1.09
Purulent pericarditis. Postgrad Med J (1989) 1.00
Primary Streptococcus pneumoniae pericarditis. Proc (Bayl Univ Med Cent) (2013) 0.89
Fusobacterium nucleatum pericarditis. J Clin Microbiol (1983) 0.88
Primary meningococcal pericarditis complicated by acute renal failure. Thorax (1979) 0.86
Primary meningococcal pericarditis with tamponade. Postgrad Med J (1985) 0.82
Cardiac tamponade due to actinomycosis. Thorax (1984) 0.81
Purulent pericarditis caused by Haemophilus parainfluenzae. Tex Heart Inst J (2013) 0.79
Purulent and constrictive pericarditis arising from a staphylococcal lumbar infection. Tex Heart Inst J (2001) 0.78
Cardiac tamponade. Br Med J (1980) 0.75
Bacteriologic profile of pericardial infections after cardiac surgery: study in an Iranian cardiovascular tertiary care center. Res Cardiovasc Med (2014) 0.75
Streptococcus pneumoniae-associated pneumonia complicated by purulent pericarditis: case series. J Bras Pneumol (2015) 0.75
Occult purulent pericarditis detected by indium-111 leukocyte imaging. Chest (1984) 0.75
Acute Primary Pneumococcal Purulent Pericarditis With Cardiac Tamponade: A Case Report and Literature Review. Medicine (Baltimore) (2015) 0.75
Pericarditis caused by beta-lactamase-producing Haemophilus influenzae: report of two cases in adults and review of the literature. Tex Heart Inst J (1986) 0.75
Pneumococcal pericarditis presenting as an out of hospital cardiopulmonary arrest. J Accid Emerg Med (1997) 0.75
Polymicrobial Purulent Pericarditis Probably caused by a Broncho-Lymph Node-Pericardial Fistula in a Patient with Tuberculous Lymphadenitis. Infect Chemother (2015) 0.75
Staphylococcal pericarditis-successful nonsurgical treatment with indwelling catheter and antibiotic drugs. West J Med (1982) 0.75
Bacterial pericarditis and tamponade due to nonencapsulated Haemophilus influenzae complicating a case of adult community-acquired pneumonia. MedGenMed (2006) 0.75
A rare complication of a pneumococcal pneumonia. Neth Heart J (2009) 0.75
Bubbles in the Pericardium. Am J Case Rep (2015) 0.75
Hemophilus influenzae pericarditis in two adults. West J Med (1986) 0.75
Pericarditis due to Bacteroides melaninogenicus secondary to a teratoma. Thorax (1988) 0.75
In vitro activity and mechanism of action of A21978C1, a novel cyclic lipopeptide antibiotic. Antimicrob Agents Chemother (1985) 7.83
In vitro activity of ciprofloxacin, a new carboxyquinoline antimicrobial agent. Antimicrob Agents Chemother (1984) 7.14
Infection in organ-transplant recipients. N Engl J Med (1998) 6.49
Studies on antibiotic synergism against enterococci. I. Bacteriologic studies. J Lab Clin Med (1971) 6.08
Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet (2001) 5.90
Outbreak of ceftazidime resistance caused by extended-spectrum beta-lactamases at a Massachusetts chronic-care facility. Antimicrob Agents Chemother (1990) 5.81
In vitro and in vivo activity of LY 146032, a new cyclic lipopeptide antibiotic. Antimicrob Agents Chemother (1986) 5.30
Species-specific resistance to antimocrobial synergism in Streptococcus faecium and Streptococcus faecalis. J Infect Dis (1979) 4.70
Rapid dissemination of beta-lactamase-producing, aminoglycoside-resistant Enterococcus faecalis among patients and staff on an infant-toddler surgical ward. N Engl J Med (1990) 4.40
Antimicrobial-drug resistance. N Engl J Med (1996) 4.07
Infections with Acinetobacter calcoaceticus (Herellea vaginicola): clinical and laboratory studies. Medicine (Baltimore) (1977) 4.05
In-vitro activity of Sch 29482 in comparison with other oral antibiotics. J Antimicrob Chemother (1982) 3.95
Activity and mechanism of action of DuP 105 and DuP 721, new oxazolidinone compounds. J Antimicrob Chemother (1988) 3.80
In vitro activity of CP-99,219, a new fluoroquinolone, against clinical isolates of gram-positive bacteria. Antimicrob Agents Chemother (1993) 3.80
Analysis of T lymphocyte subsets in cytomegalovirus mononucleosis. J Immunol (1981) 3.71
Use of monoclonal antibodies to T-cell subsets for immunologic monitoring and treatment in recipients of renal allografts. N Engl J Med (1981) 3.63
Mechanism of resistance to antibiotic synergism in enterococci. J Bacteriol (1971) 3.59
Diphtheroid prosthetic valve endocarditis. A study of clinical features and infecting organisms. Am J Med (1980) 3.59
Synergy of penicillin and gentamicin against Enterococci. J Infect Dis (1971) 3.55
Identification of streptococci: use of lysozyme and Streptomyces albus filtrate in the preparation of extracts for Lancefield grouping. J Clin Microbiol (1975) 3.53
Resistance to six aminoglycosidic aminocyclitol antibiotics among enterococci: prevalence, evolution, and relationship to synergism with penicillin. Antimicrob Agents Chemother (1977) 3.27
Penicillin and gentamicin therapy for enterococcal infections. JAMA (1973) 3.07
Increasing resistance to beta-lactam antibiotics among clinical isolates of Enterococcus faecium: a 22-year review at one institution. Antimicrob Agents Chemother (1991) 3.00
Salmonella typhimurium resistant to silver nitrate, chloramphenicol, and ampicillin. Lancet (1975) 3.00
Retrospective study of the toxicity of preparations of vancomycin from 1974 to 1981. Antimicrob Agents Chemother (1983) 2.99
Susceptibility of enterococci and Listeria monocytogenes to N-Formimidoyl thienamycin alone and in combination with an aminoglycoside. Antimicrob Agents Chemother (1981) 2.88
Mechanism of action and in vitro and in vivo activities of S-6123, a new oxazolidinone compound. Antimicrob Agents Chemother (1988) 2.83
Penicillin-tobramycin synergism against enterococci: a comparison with penicillin and gentamicin. Antimicrob Agents Chemother (1973) 2.83
International Conference for the Development of a Consensus on the Management and Prevention of Severe Candidal Infections. Clin Infect Dis (1997) 2.78
Resistance to beta-lactam antibiotics in Streptococcus faecium. Antimicrob Agents Chemother (1982) 2.68
Vancomycin therapy in patients with impaired renal function: a nomogram for dosage. Ann Intern Med (1981) 2.68
The enterococcus: "putting the bug in our ears". Ann Intern Med (1987) 2.59
High-level resistance to gentamicin in clinical isolates of Streptococcus (Enterococcus) faecium. Antimicrob Agents Chemother (1988) 2.59
A gene conferring resistance to vancomycin but not teicoplanin in isolates of Enterococcus faecalis and Enterococcus faecium demonstrates homology with vanB, vanA, and vanC genes of enterococci. Antimicrob Agents Chemother (1993) 2.56
Studies on antibiotic syngerism against enterococci. II. Effect of various antibiotics on the uptake of 14 C-labeled streptomycin by enterococci. J Clin Invest (1971) 2.49
Single-dose kinetics of intravenous vancomycin. J Clin Pharmacol (1980) 2.48
Aminoglycoside-inactivating enzymes in clinical isolates of Streptococcus faecalis. An explanation for resistance to antibiotic synergism. J Clin Invest (1978) 2.48
Infective endocarditis--1973. Prog Cardiovasc Dis (1974) 2.42
Endocarditis due to group D streptococci. Comparison of disease caused by streptococcus bovis with that produced by the enterococci. Am J Med (1974) 2.39
Antimicrobial synergism--an elusive concept. J Infect Dis (1979) 2.39
Antibiotic synergism against Listeria monocytogenes. Antimicrob Agents Chemother (1972) 2.36
Continuous-infusion ampicillin therapy of enterococcal endocarditis in rats. Antimicrob Agents Chemother (1987) 2.35
Efficacy of single-dose and conventional amoxicillin therapy in urinary-tract infection localized by the antibody-coated bacteria technic. N Engl J Med (1978) 2.33
In vitro activity of RP59500, an injectable streptogramin antibiotic, against vancomycin-resistant gram-positive organisms. Antimicrob Agents Chemother (1993) 2.29
Recovery of resistance (R) factors from a drug-free community. Lancet (1969) 2.26
Treatment of acute renal allograft rejection with OKT3 monoclonal antibody. Transplantation (1981) 2.22
Hepatic abscess: changes in clinical, bacteriologic and therapeutic aspects. Am J Med (1974) 2.21
Drug therapy: The newer cephalosporins. N Engl J Med (1976) 2.20
SME-type carbapenem-hydrolyzing class A beta-lactamases from geographically diverse Serratia marcescens strains. Antimicrob Agents Chemother (2000) 2.15
Molecular epidemiology of adhesin and hemolysin virulence factors among uropathogenic Escherichia coli. Infect Immun (1989) 2.12
Studies on the mechanism of intrinsic resistance to beta-lactam antibiotics in group D streptococci. J Gen Microbiol (1983) 2.10
Antecedents of cardiovascular disease in six Solomon Islands societies. Circulation (1974) 2.08
Prevalence of high-level resistance to aminoglycosides in clinical isolates of enterococci. Antimicrob Agents Chemother (Bethesda) (1970) 2.07
Resistance to gentamicin, tobramycin and amikacin among clinical isolates of bacteria. Am J Med (1977) 2.07
In vitro activities of the quinolone antimicrobial agents A-56619 and A-56620. Antimicrob Agents Chemother (1985) 1.99
In vitro activity of RU 64004, a new ketolide antibiotic, against gram-positive bacteria. Antimicrob Agents Chemother (1997) 1.96
Efficacy of different beta-lactams against an extended-spectrum beta-lactamase-producing Klebsiella pneumoniae strain in the rat intra-abdominal abscess model. Antimicrob Agents Chemother (1991) 1.94
Resistance to penicillin-streptomycin synergy among clinical isolates of viridans streptococci. Antimicrob Agents Chemother (1983) 1.93
The release of four mediators of immediate hypersensitivity from human leukemic basophils. J Immunol (1975) 1.92
Technetium-99m-human polyclonal IgG radiolabeled via the hydrazino nicotinamide derivative for imaging focal sites of infection in rats. J Nucl Med (1990) 1.92
Plasmid-mediated resistance to antibiotic synergism in enterococci. J Clin Invest (1978) 1.90
Susceptibility of clinical isolates of bacteria to cefoxitin and cephalothin. Antimicrob Agents Chemother (1974) 1.86
Controlled clinical trial of prophylactic human-leukocyte interferon in renal transplantation. Effects on cytomegalovirus and herpes simplex virus infections. N Engl J Med (1979) 1.83
In vitro activities of two glycylcyclines against gram-positive bacteria. Antimicrob Agents Chemother (1994) 1.82
Glomerulopathy associated with cytomegalovirus viremia in renal allografts. N Engl J Med (1981) 1.77
Chromosomally mediated beta-lactamase production and gentamicin resistance in Enterococcus faecalis. Antimicrob Agents Chemother (1991) 1.75
BK virus in solid organ transplant recipients: an emerging syndrome. Transplantation (2001) 1.75
Multiply resistant viridans streptococci: susceptibility to beta-lactam antibiotics and comparison of penicillin-binding protein patterns. Antimicrob Agents Chemother (1983) 1.74
Enterococcal infections in patients treated with moxalactam. Rev Infect Dis (1983) 1.72
Comparative in vitro activity of WIN 57273, a new fluoroquinolone antimicrobial agent. Antimicrob Agents Chemother (1990) 1.71
Susceptibility of pneumococci to 14 beta-lactam agents: comparison of strains resistant, intermediate-resistant, and susceptible to penicillin. Antimicrob Agents Chemother (1981) 1.67
Imaging focal sites of bacterial infection in rats with indium-111-labeled chemotactic peptide analogs. J Nucl Med (1991) 1.65
Characterization of vancomycin-resistant Enterococcus faecium isolates from the United States and their susceptibility in vitro to dalfopristin-quinupristin. Antimicrob Agents Chemother (1998) 1.63
Patterns and mechanisms of antibiotic resistance. Med Clin North Am (1978) 1.63
Cephalothin prophylaxis in cardiac valve surgery. A prospective, double-blind comparison of two-day and six-day regimens. J Thorac Cardiovasc Surg (1977) 1.60
Effect of protein binding on the activity of penicillins in combination with gentamicin against enterococci. Antimicrob Agents Chemother (1979) 1.60
Multiply high-level-aminoglycoside-resistant enterococci isolated from patients in a university hospital. J Clin Microbiol (1988) 1.58
In vitro activity of BMY-28100, a new oral cephalosporin. Antimicrob Agents Chemother (1987) 1.56
Azlocillin, mezlocillin, and piperacillin: new broad-spectrum penicillins. Ann Intern Med (1982) 1.55
Pharmacokinetics of 18F-labeled fluconazole in healthy human subjects by positron emission tomography. Antimicrob Agents Chemother (1993) 1.55
Resistance to cefamandole: a collaborative study of emerging clinical problems. J Infect Dis (1982) 1.54
Absence of synergistic activity between ampicillin and vancomycin against highly vancomycin-resistant enterococci. Antimicrob Agents Chemother (1992) 1.53
Aminoglycoside-modifying enzymes among clinical isolates of Acinetobacter calcoaceticus subsp. anitratus (Herellea vaginicola): explanation for high-level aminoglycoside resistance. Antimicrob Agents Chemother (1979) 1.52
Chronic Epstein-Barr virus infection associated with fever and interstitial pneumonitis. Clinical and serologic features and response to antiviral chemotherapy. Ann Intern Med (1986) 1.48
Treatment of experimental endocarditis caused by a beta-lactamase-producing strain of Enterococcus faecalis with high-level resistance to gentamicin. Antimicrob Agents Chemother (1989) 1.47
Ribosomal resistance of clinical enterococcal to streptomycin isolates. Antimicrob Agents Chemother (1984) 1.45
Adverse reactions to duck embryo rabies vaccine. Range and incidence. Ann Intern Med (1973) 1.44
Antimicrobial susceptibility of flavobacteria. Antimicrob Agents Chemother (1978) 1.44
Single-dose amoxicillin therapy for urinary tract infection. Multicenter trial using antibody-coated bacteria localization technique. JAMA (1980) 1.43
In vitro activities in new oxazolidinone antimicrobial agents against enterococci. Antimicrob Agents Chemother (1996) 1.42
Infectious disease syndromes attributable to cytomegalovirus and their significance among renal transplant recipients. Transplantation (1977) 1.40
Efficacy of oxacillin and ampicillin-sulbactam combination in experimental endocarditis caused by beta-lactamase-hyperproducing Staphylococcus aureus. Antimicrob Agents Chemother (1990) 1.40
In-vivo acquisition of two different types of aminoglycoside resistance by a single strain of Klebsiella pneumoniae causing severe infection. Ann Intern Med (1982) 1.39
The therapeutic prescription for the transplant patient. Transpl Infect Dis (2002) 1.39
Efficacies of piperacillin-tazobactam and cefepime in rats with experimental intra-abdominal abscesses due to an extended-spectrum beta-lactamase-producing strain of Klebsiella pneumoniae. Antimicrob Agents Chemother (1997) 1.39
Evidence of plasmid-mediated production of aminoglycoside-modifying enzymes not previously described in Acinetobacter. Antimicrob Agents Chemother (1980) 1.39
Effects of azlocillin in combination with clavulanic acid, sulbactam, and N-formimidoyl thienamycin against beta-lactamase-producing, carbenicillin-resistant Pseudomonas aeruginosa. Antimicrob Agents Chemother (1982) 1.38
In search of the hot appendix--a clinician's view of inflammation imaging. J Nucl Med (1990) 1.38
Hemophilus influenzae in hospitalized adults: current perspectives. Am J Med (1980) 1.38